Currently, there are 164.67M common shares owned by the public and among those 137.26M shares have been available to trade.
The company’s stock has a 5-day price change of 13.17% and 37.64% over the past three months. RVMD shares are trading 53.14% year to date (YTD), with the 12-month market performance up to 66.43% higher. It has a 12-month low price of $15.44 and touched a high of $41.21 over the same period. RVMD has an average intraday trading volume of 1.32 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 13.86%, 13.96%, and 43.99% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Revolution Medicines Inc (NASDAQ: RVMD) shares accounts for 82.64% of the company’s 164.67M shares outstanding.
It has a market capitalization of $7.25B and a beta (3y monthly) value of 1.44. The earnings-per-share (ttm) stands at -$3.76. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.04% over the week and 3.58% over the month.
Earnings per share for the fiscal year are expected to increase by 19.72%, and -12.86% over the next financial year.
Looking at the support for the RVMD, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on July 08, 2024, with the firm’s price target at $63. Needham coverage for the Revolution Medicines Inc (RVMD) stock in a research note released on April 12, 2024 offered a Buy rating with a price target of $46. Raymond James was of a view on April 10, 2024 that the stock is Strong Buy, while Piper Sandler gave the stock Overweight rating on March 11, 2024, issuing a price target of $43. BofA Securities on their part issued Buy rating on January 05, 2024.
